1.57BMarket Cap
LossP/E TTM
Key Figures
76.620Open
76.740High
794.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
5.71%Turnover Ratio
76.980Prev. Close
76.540Low
30.28MTurnover
LossP/E Static
25.31P/B
0.00%Div Yield TTM
-132.29%ROA
35.80052wk High
0.13Volume Ratio
-35.48MNet Profit
13.91MShares
-4.5812EPS TTM
2.91Beta
-188.40%ROE
7.78052wk Low
0.26%Amplitude
--Gross Margin
1.57BMarket Cap
36.66Reward/Risk
7.56%Risk Rate
Currency: USD Updated: 2026-07-31 Key Insights
Forte Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 73.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Forte Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Forte Biosciences Inc Highlights
StrengthsRisks
Forte Biosciences Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Forte Biosciences Inc
FBRX
5
Ionis Pharmaceuticals Inc
IONS
27
Kymera Therapeutics Inc
KYMR
24
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Forte Biosciences Inc Info
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Ticker SymbolFBRX
CompanyForte Biosciences Inc
CEOWagner (Paul A)
Websitehttps://www.fortebiorx.com/home/default.aspx
Shareholders
FAQs
What is the current price of Forte Biosciences Inc (FBRX)?
The current price of Forte Biosciences Inc (FBRX) is 76.60.
What is the symbol of Forte Biosciences Inc?
The ticker symbol of Forte Biosciences Inc is FBRX.
What is the 52-week high of Forte Biosciences Inc?
The 52-week high of Forte Biosciences Inc is 35.80.
What is the 52-week low of Forte Biosciences Inc?
The 52-week low of Forte Biosciences Inc is 7.78.
What is the market capitalization of Forte Biosciences Inc?
The market capitalization of Forte Biosciences Inc is 1.57B.
Is Forte Biosciences Inc (FBRX) currently rated as Buy, Hold, or Sell?
According to analysts, Forte Biosciences Inc (FBRX) has an overall rating of signal_hold, with a price target of 73.80.
What is the Earnings Per Share (EPS TTM) of Forte Biosciences Inc (FBRX)?
The Earnings Per Share (EPS TTM) of Forte Biosciences Inc (FBRX) is -4.71.
